Navigation Links
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Date:3/9/2009

Overall, the two studies enrolled and randomized a total of 2264 treatment-naive patients.

The dose modification in January 2008 was recommended by the independent Data Monitoring Committee (DMC) based upon an interim analysis that serious pulmonary adverse events appeared to be higher in the 1200-mcg albinterferon alfa-2b treatment group.

  • Across the two Phase 3 trials, which have now been completed, rates of serious respiratory, thoracic or mediastinal disorders were: 0.7% (5/755) for 900-mcg albinterferon alfa-2b; 1.5% (11/750) for the group originally randomized to receive 1200-mcg albinterferon alfa-2b, and 0.0% (0/750) for peginterferon alfa-2a.
  • Central blinded review of chest X-rays recommended by the DMC for patients participating in the two Phase 3 trials demonstrated that the overall rates of significant interstitial findings were comparable in all three treatment groups: 4.3% (20/469) in patients randomized to receive 900-mcg albinterferon alfa-2b; 4.8% (22/454) in patients originally randomized to receive 1200-mcg albinterferon alfa-2b; and 4.5% (22/484) in patients randomized to receive 180-mcg peginterferon alfa-2a.

The incidence of fatality in the albinterferon alfa-2b Phase 3 trials was rare. All-cause mortality rates were: 0.13% (1/756) in patients randomized to receive 900-mcg albinterferon alfa-2b every two weeks; 0.53% (4/751) in patients originally randomized to receive 1200-mcg albinterferon alfa-2b every two weeks; and 0.27% (2/751) in patients randomized to receive 180-mcg peginterferon alfa-2a once-weekly.

Across the two Phase 3 trials, the overall percentage of patients who had a serious and/or severe adverse event or discontinued due to an adverse event was comparable in all dose groups: 23.2% (175/755) in patients randomized to receive 900-mcg albinterferon alfa-2b; 26.0% (195/750) in patients randomized to r
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Drug Development Program Started Based on CAP(R) Human Cell Line
2. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
3. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
4. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
5. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
6. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
9. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
10. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
11. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... REDWOOD CITY, Calif., Dec. 18, 2014 ... on the development of medical diagnostics based on ... of gas flow, today announced financial results for ... 30, 2014. "Following the completion of ... well positioned to maximize the recently initiated CoSense® ...
(Date:12/19/2014)... 2014   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... from its pivotal field study of AT-001 (Grapiprant), ... dogs with osteoarthritis.  In the study, dogs receiving ... were statistically significant compared to placebo (p<0.05) at ...
(Date:12/17/2014)... Alemania, December 17, 2014 Los ... con un alto nivel de gasto en investigación y ... 2013/14 (finalizado el 30 de septiembre de 2014) ZEISS ... 4.287 millones de euros (año anterior: 4.190 millones de ... desfavorables. Las ganancias (EBIT) crecieron un 14 por ciento, ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2
... of, a Drug Target Function. A Study Performed by Sidec and ... Two Major Conformations ... Have Been Identified, STOCKHOLM, ... direct structural evidence of the molecular mechanism,of the Synaptic Vesicle protein ...
... CardioVascular,BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) today announces ... for its Phase II clinical,trial for the treatment of ... announcing additional sites as they open for,enrollment. For current ... heart trial, please visit http://www.cvbt.com ., In ...
Cached Medicine Technology:The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC 2CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial 2
(Date:12/20/2014)... Office Urgent Care of Paramus, New Jersey has served the ... treated over 40,000 patients while carrying out their mission of ... Paramus area. , For 2015, the practice is proud ... board certified physicians: Christine Milosis MD, Sandra Ugras Rey DO, ... work tirelessly to carry out The Doctor’s Office Urgent ...
(Date:12/20/2014)... Atore, Inc, (San Francisco, CA CEO: Masashi ... focused portal on December 17th, 2014. , One ... US and Japan. , MERRY BIRTHDAY SITE : ... , MERRY BIRTHDAY MESSAGE is part of 5 future ... Features, Choose from thousands of stock photos to decorate ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Developers of ... release of a new plugin for Final Cut Pro ... , “TranSlice Volume 5 allows users to create hand ... it.” Said Christina Austin, CEO of Pixel Film Studios. ... of professionalism while maintaining an easy to use interface.” ...
(Date:12/20/2014)... 2014 Parker & Sons, Inc. a ... of experience in contractor services announces reaching a milestone ... the homeowners of Arizona. Parker and Sons is comprised ... technicians that make customer service the number one priority. ... and started with one service vehicle and has since ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with ... put to the wayside until Christmas and the New Year ... “itch” and that burning desire to just escape it all ... journey to Telluride with a no-fuss, affordable package. Montrose Days ... the resort, and ensure that all accommodations are met. Plus, ...
Breaking Medicine News(10 mins):Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2
... The American Society,for Therapeutic Radiology and Oncology is pleased ... been selected as the 2007 Survivor,Circle Award winner. Ms. ... cash prize on Sunday, October 28, 2007, at 8:00 ... Annual Meeting, which will,take place October 28 through November ...
... 16 The Center for the Internet & Digital,Medicine ... Eleanor,Herriman, MD, MBA, will chair a panel on Business ... at the 3rd Annual World,Healthcare Innovation and Technology Congress ... from 2 to 3 pm. CIDM develops and ...
... Moved Atlanta Office to Larger Space and Constructed New ... Outcomes Strategy ... ECLP ), The Outcomes Company(R), today announced,that it will move ... will take place over the next few months with,completion expected by ...
... for next-generation sensors, researchers have crafted a layered material ... manner nature never intended. , Refraction always bends light ... of a "bent" drinking straw when observed through the ... alternating layers of semiconductors (indium-gallium-arsenic and aluminum-indium-arsenic) acts as ...
... covered by current pediatric vaccine, making it tough to ... -- An emerging "superbug" that causes ear infections in ... be treated with an adult medication, researchers report. , ... strain of Streptococcus pneumoniae that caused ear ...
... Highlands Acquisition Corp.,(Amex: HIA.U), (the "Company") announced today that, ... units may elect to separately trade,the common stock and ... warrants will be quoted on the American Stock Exchange ... will continue to,trade on the American Stock Exchange under ...
Cached Medicine News:Health News:L.A. Breast Cancer Activist Honored With Survivor Circle Award 2Health News:L.A. Breast Cancer Activist Honored With Survivor Circle Award 3Health News:CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3.0 2Health News:Eclipsys Announces Relocation of Corporate Headquarters to Atlanta, GA 2Health News:Ear Infections Linked to Drug-Resistant 'Superbug' 2Health News:Ear Infections Linked to Drug-Resistant 'Superbug' 3Health News:Ear Infections Linked to Drug-Resistant 'Superbug' 4Health News:Highlands Acquisition Corp. Announces Separate Trading of Common Stock and Warrants 2
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: